Abstract
High-throughput next-generation sequencing (NGS) technologies such as whole exome sequencing (WES) and bulk RNA sequencing (RNA-seq) allow identification of the new biomarkers of response and resistance to antitumor therapy. Retrospective studies have shown that the state of the tumor microenvironment (TME), identified via RNA-seq, is an independent prognostic and predictive biomarker. WES and RNA-seq technologies, along with classical immunohistochemistry, provide a comprehensive analysis of the tumor and TME. Affordability of high-throughput sequencing will enable personalization of antitumor pharmacotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
